Developer docs
API playgroundTry for free, no card

Search company profiles

Vayamed

Full company profile

uuid000ijmt

Namestring
Vayamed
Legal namestring
Vayamed GmbH
Websiteurl
vayamed.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, incorporated in 2024 as a subsidiary of Sanity Group, that distributes standardized cannabinoid-based medicines to registered pharmacies and physicians across Germany. The company's product portfolio spans pharmaceutical-grade CBD isolate, Dronabinol (synthetic THC), medical cannabis flowers including Bedrocan 22:1 and the newly introduced Bedrocan Forte 25:1, and full-spectrum extracts, all manufactured and distributed under GMP and GDP quality standards. Vayamed holds regulatory authorization from LAGeSo Berlin and the Bundesopiumstelle, and operates a DocCheck-authenticated Fachbereich (specialist) portal that gates product information and ordering behind healthcare professional verification per §10 Heilmittelwerbegesetz. The firm is also the exclusive German wholesale partner for Bedrocan, integrated with Medios AG and Cannaflos for nationwide distribution.

The business model is B2B wholesale and professional services: revenue is generated through transactional product sales to registered pharmacies and healthcare professionals (14-day net payment, 2% skonto for SEPA direct debit within 7 days, no minimum order quantity, free shipping within Germany), supplemented by professional consultation services delivered on-site, by phone, and via digital appointments. Complementary services include the free Vayamed Cannabisausweis (patient ID card) for therapy documentation, CME-certified physician education through the DGS 'Schmerzkompetenz Cannabis' curriculum, and ongoing medical-evidence support including sponsorship of the Charité Berlin EXCARP observational study. The company serves three primary customer segments — patients with chronic or neuropathic pain, prescribing physicians and pain specialists, and dispensing pharmacies — and benefits from the April 2024 MedCanG reclassification of medical cannabis from narcotic to prescription-only status, which expanded the addressable prescribing base to approximately 76,000 contract physicians in Germany.

Short descriptiontext

Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, subsidiary of Sanity Group, that distributes GMP/GDP-certified cannabinoid medicines (CBD isolate, Dronabinol, Bedrocan flowers, extracts) to registered pharmacies and physicians across Germany.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis wholesale, cannabinoid pharmaceuticals, pharmaceutical distribution, medical cannabis therapy, specialty pharma Germany
Industry2 codes
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code3 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals / Medical Cannabis Distribution
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Wholesale - Medical Cannabis Products
TypeTransaction Fee
Description

Wholesale distribution of standardized cannabinoid-based pharmaceuticals including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts to registered pharmacies and healthcare professionals in Germany.

vayamed.com
2Professional Consultation Services
TypeProfessional Services
Description

Consultation services for healthcare professionals including on-site consultations, telephone professional support, and online professional section with information and training materials.

vayamed.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Professional healthcare customer pricing
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Net prices listed in price list (available at vayamed.com/downloads). No minimum order quantity. Payment terms: 14 days net. 2% skonto for SEPA direct debit within 7 days.

vayamed.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vayamed GmbH manufactures and distributes a portfolio of standardized, GMP/GDP-compliant cannabinoid-based pharmaceutical products—including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts—to registered pharmacies and licensed physicians across Germany. Alongside the pharmaceutical line, the company sells a free Vayamed Cannabisausweis (patient ID card) for therapy documentation and provides professional consultation and education services to prescribers and pharmacists through its specialist portal and account-managed relationships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 74% of patients reported improvement in symptoms and quality of life in BfArM observational study
+2 more records
Product overview1 text field

Vayamed offers a patient-oriented portfolio of standardized cannabinoid-based pharmaceuticals and related services. The core product range includes pharmaceutical-grade CBD isolate, dronabinol (synthetic THC), medical cannabis flowers (Bedrocan® varieties), and full-spectrum extracts—all manufactured according to GMP and GDP quality standards. The product line was expanded in 2026 to include Bedrocan® Forte 25:1 and Bedrocan® 22:1 cannabis flowers through an exclusive distribution partnership. Complementary services include the Vayamed Cannabisausweis (patient ID card) for therapy documentation, a specialist Fachbereich portal with product information and ordering, and medical/pharmaceutical education support through partnerships with DGS and other professional organizations.

Product and service7 records
1CBD Isolate (CBD-Isolat)
CategoryCannabinoid pharmaceuticals
Description

Pharmaceutical-grade CBD isolate cannabinoid product manufactured to GMP/GDP quality standards for therapeutic use in cannabinoid-based therapy.

2Dronabinol
CategoryCannabinoid pharmaceuticals
Description

Synthetic THC (tetrahydrocannabinol) pharmaceutical product for cannabinoid-based therapy, supplied to pharmacies and licensed prescribers in Germany.

3Medical Cannabis Flowers (Medizinisch relevante Cannabisblüten)
CategoryCannabinoid pharmaceuticals
Description

Standardized pharmaceutical-quality cannabis flowers for medical use, supplied by Vayamed to registered pharmacies and licensed physicians in Germany.

4Full-Spectrum Extracts (Vollspektrumextrakte)
CategoryCannabinoid pharmaceuticals
Description

Full-spectrum cannabinoid extracts containing multiple cannabis compounds, manufactured to GMP/GDP standards for enhanced therapeutic effects.

5Bedrocan® 22:1
CategoryCannabinoid pharmaceuticals
Description

Established Dutch-origin Bedrocan medical cannabis flower with a 22% THC and 1% CBD ratio, distributed by Vayamed in Germany under its exclusive Bedrocan wholesale partnership.

6Bedrocan® Forte 25:1
CategoryCannabinoid pharmaceuticals
Description

Higher-dosage Bedrocan medical cannabis flower (25% THC, 1% CBD) developed for patients requiring stronger cannabinoid therapy; introduced to the German market in April 2026 under Vayamed's exclusive Bedrocan wholesale partnership.

7Vayamed Cannabisausweis (Patient ID Card)
CategoryPatient services / therapy documentation
Description

Free personalized patient identification card certifying authorized use of prescribed cannabinoid medications, intended to support patients during police controls and document ongoing therapy.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

Parent company of Vayamed GmbH. Vayamed operates as a subsidiary specializing in medical cannabinoid products. Sanity Group founder Finn Hänsel serves as managing director of Vayamed.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-23
Description

Leading Specialty Pharma provider in Europe, exclusive distribution partner of Bedrocan for Germany since 2026. Vayamed integrated as exclusive wholesale partner within their distribution network alongside Cannaflos.

3Cannaflos - Gesellschaft für medizinisches Cannabis mbH
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-23
Description

Distribution partner supporting Medios AG in building nationwide distribution network in Germany. Works with Vayamed as exclusive wholesale partner within the distribution chain.

vayamed.com
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-04-23
Description

Dutch manufacturer of standardized medical cannabis products. Vayamed distributes Bedrocan products including Bedrocan 22:1 and Bedrocan Forte 25:1 cannabis flowers in Germany.

Strategic tierMinorTypeOthers
Description

German pharmaceutical industry association advocating for policy supporting pharmaceutical innovation and sustainable healthcare. Vayamed holds membership.

6Deutsche Gesellschaft für Schmerzmedizin e.V. (DGS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Largest medical pain therapy society in Europe. Vayamed is the only pharmaceutical company supporting the DGS Pain Initiative Cannabinoids and sponsoring DGS Curriculum 'Schmerzkompetenz Cannabis' with scholarships.

vayamed.com
7Deutsche Schmerzliga e.V.
Strategic tierMinorTypeOthers
Description

Patient organization for chronic pain patients advocating for quality pain therapy and patient rights to competent treatment. Vayamed maintains partnership.

vayamed.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Vayamed supported the EXCARP observational study conducted by Charité Hochschulambulanz für Naturheilkunde examining patient perspectives on prescription cannabinoid therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German medical cannabis wholesaler and pharmacy platform offering standardized cannabis products and digital ordering tools. Competes with Vayamed in the same physician/pharmacy channel and has been active in advocating for streamlined German cannabis prescribing frameworks.

2Avaay (Sanity Group)
TypeOthers
Description

Sister brand of Vayamed under the Sanity Group umbrella, focused on medical cannabis e-commerce. Operates the Apo Online Shop accessed via vayamed.com and represents the parent group's adjacent channel rather than a direct competitor.

TypeBroad incumbent
Description

Canadian cannabis multinational with established German medical cannabis operations via its Storz & Bickel vaporizer subsidiary partnership network. Competes with Vayamed in the broader medical cannabis and cannabinoid therapy ecosystem in Germany.

TypeDirect peer
Description

High Tide's German subsidiary actively competes with Vayamed in medical cannabis wholesale to German pharmacies. Notable as Vayamed's most direct legal adversary in the Berlin Court injunction case, indicating direct competition in physician and pharmacy channels for standardized medical cannabis products.

TypeDirect peer
Description

Germany-based medical cannabis wholesaler with similar GACP/GMP-certified product portfolio and pharmacy distribution model. Operates as a direct competitor in supplying standardized cannabis flowers and extracts to German pharmacies, with comparable focus on physician education.

TypeBroad incumbent
Description

Large Canadian cannabis producer with established European medical cannabis operations, including Germany. Competes with Vayamed in the wholesale supply of standardized medical cannabis flowers to German pharmacies and leverages its vertically integrated cultivation footprint similar to Vayamed's partnership with Bedrocan.

7Tilray Brands
TypeBroad incumbent
Description

Global cannabis leader with significant German medical cannabis distribution operations. Competes directly with Vayamed in the German pharmacy wholesale channel and offers a comparable portfolio of standardized medical cannabis flowers and extracts, but at much larger scale and broader geographic footprint.

TypeOthers
Description

German vaporizer manufacturer that is both a Vayamed technology/integration partner and part of Canopy Growth. Provides medical devices for cannabinoid administration and represents a complementary, not directly competitive, player in the German medical cannabis ecosystem.

9Bedrocan International
TypeOthers
Description

Dutch producer of standardized medical cannabis flowers and Vayamed's exclusive German wholesale partner. Closely economically linked but operates upstream of Vayamed; relevant for understanding Vayamed's product differentiation and supply continuity risks.

TypeDirect peer
Description

Vertically integrated German medical cannabis producer-distributor cultivating domestically and wholesaling standardized flower products to German pharmacies. Directly competes with Vayamed's imported flower portfolio with a 'Made in Germany' positioning advantage.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vayamed

Specialty Pharmaceuticals / Medical Cannabis Distributionvayamed.com

Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, subsidiary of Sanity Group, that distributes GMP/GDP-certified cannabinoid medicines (CBD isolate, Dronabinol, Bedrocan flowers, extracts) to registered pharmacies and physicians across Germany.

What Vayamed does

Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, incorporated in 2024 as a subsidiary of Sanity Group, that distributes standardized cannabinoid-based medicines to registered pharmacies and physicians across Germany. The company's product portfolio spans pharmaceutical-grade CBD isolate, Dronabinol (synthetic THC), medical cannabis flowers including Bedrocan 22:1 and the newly introduced Bedrocan Forte 25:1, and full-spectrum extracts, all manufactured and distributed under GMP and GDP quality standards. Vayamed holds regulatory authorization from LAGeSo Berlin and the Bundesopiumstelle, and operates a DocCheck-authenticated Fachbereich (specialist) portal that gates product information and ordering behind healthcare professional verification per §10 Heilmittelwerbegesetz. The firm is also the exclusive German wholesale partner for Bedrocan, integrated with Medios AG and Cannaflos for nationwide distribution.

The business model is B2B wholesale and professional services: revenue is generated through transactional product sales to registered pharmacies and healthcare professionals (14-day net payment, 2% skonto for SEPA direct debit within 7 days, no minimum order quantity, free shipping within Germany), supplemented by professional consultation services delivered on-site, by phone, and via digital appointments. Complementary services include the free Vayamed Cannabisausweis (patient ID card) for therapy documentation, CME-certified physician education through the DGS 'Schmerzkompetenz Cannabis' curriculum, and ongoing medical-evidence support including sponsorship of the Charité Berlin EXCARP observational study. The company serves three primary customer segments — patients with chronic or neuropathic pain, prescribing physicians and pain specialists, and dispensing pharmacies — and benefits from the April 2024 MedCanG reclassification of medical cannabis from narcotic to prescription-only status, which expanded the addressable prescribing base to approximately 76,000 contract physicians in Germany.

Vayamed firmographics

Firmographics
Name
Vayamed
Legal name
Vayamed GmbH
Website
https://vayamed.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Vayamed GmbH is a Berlin-based pharmaceutical wholesaler, subsidiary of Sanity Group, that distributes GMP/GDP-certified cannabinoid medicines (CBD isolate, Dronabinol, Bedrocan flowers, extracts) to registered pharmacies and physicians across Germany.
Ownership category
akta.pro rank

Vayamed industry classification

Industry
Product category
Specialty Pharmaceuticals / Medical Cannabis Distribution
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medical cannabis wholesale
  • Cannabinoid pharmaceuticals
  • Pharmaceutical distribution
  • Medical cannabis therapy
  • Specialty pharma Germany

Where Vayamed is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Vayamed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Pharmaceutical Wholesale - Medical Cannabis Products: Wholesale distribution of standardized cannabinoid-based pharmaceuticals including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts to registered pharmacies and healthcare professionals in Germany.
  2. Professional Consultation Services: Consultation services for healthcare professionals including on-site consultations, telephone professional support, and online professional section with information and training materials.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goProfessional healthcare customer pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Vayamed product offering

Product offering

Core offering

Vayamed GmbH manufactures and distributes a portfolio of standardized, GMP/GDP-compliant cannabinoid-based pharmaceutical products—including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts—to registered pharmacies and licensed physicians across Germany. Alongside the pharmaceutical line, the company sells a free Vayamed Cannabisausweis (patient ID card) for therapy documentation and provides professional consultation and education services to prescribers and pharmacists through its specialist portal and account-managed relationships.

Product overview

Vayamed offers a patient-oriented portfolio of standardized cannabinoid-based pharmaceuticals and related services. The core product range includes pharmaceutical-grade CBD isolate, dronabinol (synthetic THC), medical cannabis flowers (Bedrocan® varieties), and full-spectrum extracts—all manufactured according to GMP and GDP quality standards. The product line was expanded in 2026 to include Bedrocan® Forte 25:1 and Bedrocan® 22:1 cannabis flowers through an exclusive distribution partnership. Complementary services include the Vayamed Cannabisausweis (patient ID card) for therapy documentation, a specialist Fachbereich portal with product information and ordering, and medical/pharmaceutical education support through partnerships with DGS and other professional organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • CBD Isolate (CBD-Isolat) Pharmaceutical-grade CBD isolate cannabinoid product manufactured to GMP/GDP quality standards for therapeutic use in cannabinoid-based therapy.
  • Dronabinol Synthetic THC (tetrahydrocannabinol) pharmaceutical product for cannabinoid-based therapy, supplied to pharmacies and licensed prescribers in Germany.
  • Medical Cannabis Flowers (Medizinisch relevante Cannabisblüten) Standardized pharmaceutical-quality cannabis flowers for medical use, supplied by Vayamed to registered pharmacies and licensed physicians in Germany.
  • Full-Spectrum Extracts (Vollspektrumextrakte) Full-spectrum cannabinoid extracts containing multiple cannabis compounds, manufactured to GMP/GDP standards for enhanced therapeutic effects.
  • Bedrocan® 22:1 Established Dutch-origin Bedrocan medical cannabis flower with a 22% THC and 1% CBD ratio, distributed by Vayamed in Germany under its exclusive Bedrocan wholesale partnership.
  • Bedrocan® Forte 25:1 Higher-dosage Bedrocan medical cannabis flower (25% THC, 1% CBD) developed for patients requiring stronger cannabinoid therapy; introduced to the German market in April 2026 under Vayamed's exclusive Bedrocan wholesale partnership.
  • Vayamed Cannabisausweis (Patient ID Card) Free personalized patient identification card certifying authorized use of prescribed cannabinoid medications, intended to support patients during police controls and document ongoing therapy.

Quantifiable outcome

  • 74% of patients reported improvement in symptoms and quality of life in BfArM observational study
  • +2 more outcomes

Companies that use Vayamed

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Vayamed technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature2 records

Vayamed partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, major and minor.

  • Sanity GroupcoreStrategic or Co-development Partner · 23 April 2026Parent company of Vayamed GmbH. Vayamed operates as a subsidiary specializing in medical cannabinoid products. Sanity Group founder Finn Hänsel serves as managing director of Vayamed.
  • Medios AGcoreChannel Partner/ Reseller/ Distributor · 23 April 2026Leading Specialty Pharma provider in Europe, exclusive distribution partner of Bedrocan for Germany since 2026. Vayamed integrated as exclusive wholesale partner within their distribution network alongside Cannaflos.
  • Cannaflos - Gesellschaft für medizinisches Cannabis mbHmajorChannel Partner/ Reseller/ Distributor · 23 April 2026Distribution partner supporting Medios AG in building nationwide distribution network in Germany. Works with Vayamed as exclusive wholesale partner within the distribution chain.
  • BedrocanmajorTechnology or Integration · 23 April 2026Dutch manufacturer of standardized medical cannabis products. Vayamed distributes Bedrocan products including Bedrocan 22:1 and Bedrocan Forte 25:1 cannabis flowers in Germany.
  • Bundesverband der Pharmazeutischen Industrie (BPI)minorOthersGerman pharmaceutical industry association advocating for policy supporting pharmaceutical innovation and sustainable healthcare. Vayamed holds membership.
  • Deutsche Gesellschaft für Schmerzmedizin e.V. (DGS)coreStrategic or Co-development PartnerLargest medical pain therapy society in Europe. Vayamed is the only pharmaceutical company supporting the DGS Pain Initiative Cannabinoids and sponsoring DGS Curriculum 'Schmerzkompetenz Cannabis' with scholarships.
  • Deutsche Schmerzliga e.V.minorOthersPatient organization for chronic pain patients advocating for quality pain therapy and patient rights to competent treatment. Vayamed maintains partnership.
  • Charité Berlin / Immanuel Krankenhaus BerlinmajorStrategic or Co-development PartnerVayamed supported the EXCARP observational study conducted by Charité Hochschulambulanz für Naturheilkunde examining patient perspectives on prescription cannabinoid therapies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Vayamed competitors and assessment

Company assessment

Direct peers

  • Nimbus Health (now part of Cansativa): German medical cannabis wholesaler and pharmacy platform offering standardized cannabis products and digital ordering tools. Competes with Vayamed in the same physician/pharmacy channel and has been active in advocating for streamlined German cannabis prescribing frameworks.
  • Remexian Pharma (High Tide): High Tide's German subsidiary actively competes with Vayamed in medical cannabis wholesale to German pharmacies. Notable as Vayamed's most direct legal adversary in the Berlin Court injunction case, indicating direct competition in physician and pharmacy channels for standardized medical cannabis products.
  • Cannamedical Pharma: Germany-based medical cannabis wholesaler with similar GACP/GMP-certified product portfolio and pharmacy distribution model. Operates as a direct competitor in supplying standardized cannabis flowers and extracts to German pharmacies, with comparable focus on physician education.
  • Demecan: Vertically integrated German medical cannabis producer-distributor cultivating domestically and wholesaling standardized flower products to German pharmacies. Directly competes with Vayamed's imported flower portfolio with a 'Made in Germany' positioning advantage.

Others

  • Avaay (Sanity Group): Sister brand of Vayamed under the Sanity Group umbrella, focused on medical cannabis e-commerce. Operates the Apo Online Shop accessed via vayamed.com and represents the parent group's adjacent channel rather than a direct competitor.
  • Storz & Bickel GmbH (Canopy Growth): German vaporizer manufacturer that is both a Vayamed technology/integration partner and part of Canopy Growth. Provides medical devices for cannabinoid administration and represents a complementary, not directly competitive, player in the German medical cannabis ecosystem.
  • Bedrocan International: Dutch producer of standardized medical cannabis flowers and Vayamed's exclusive German wholesale partner. Closely economically linked but operates upstream of Vayamed; relevant for understanding Vayamed's product differentiation and supply continuity risks.

Broad incumbents

  • Canopy Growth Corporation: Canadian cannabis multinational with established German medical cannabis operations via its Storz & Bickel vaporizer subsidiary partnership network. Competes with Vayamed in the broader medical cannabis and cannabinoid therapy ecosystem in Germany.
  • Aurora Cannabis: Large Canadian cannabis producer with established European medical cannabis operations, including Germany. Competes with Vayamed in the wholesale supply of standardized medical cannabis flowers to German pharmacies and leverages its vertically integrated cultivation footprint similar to Vayamed's partnership with Bedrocan.
  • Tilray Brands: Global cannabis leader with significant German medical cannabis distribution operations. Competes directly with Vayamed in the German pharmacy wholesale channel and offers a comparable portfolio of standardized medical cannabis flowers and extracts, but at much larger scale and broader geographic footprint.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Vayamed social profiles

Digital presence

Vayamed compliance and trust

Trust signal

Compliance2 records

Vayamed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vayamed leadership team

Management profile

Number of profiles

Profiles2 records

Vayamed funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vayamed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vayamed

What does Vayamed do?

Vayamed GmbH manufactures and distributes a portfolio of standardized, GMP/GDP-compliant cannabinoid-based pharmaceutical products—including CBD isolate, Dronabinol, medical cannabis flowers, and full-spectrum extracts—to registered pharmacies and licensed physicians across Germany. Alongside the pharmaceutical line, the company sells a free Vayamed Cannabisausweis (patient ID card) for therapy documentation and provides professional consultation and education services to prescribers and pharmacists through its specialist portal and account-managed relationships.

Is Vayamed a public or private company?

Vayamed is a private company. It is classified as corporate owned and is currently operating.

When was Vayamed founded?

Vayamed was founded in 2024. It employs 11 to 50 people.

Where is Vayamed based?

Vayamed is headquartered in Berlin, Germany, in the Europe region.

How does Vayamed make money?

Two revenue lines are on record. Pharmaceutical Wholesale - Medical Cannabis Products are the primary driver. The others are professional Consultation Services.

Who are Vayamed's main competitors?

Direct peers on record are Nimbus Health (now part of Cansativa), Remexian Pharma (High Tide), Cannamedical Pharma and Demecan. Others are Avaay (Sanity Group), Storz & Bickel GmbH (Canopy Growth) and Bedrocan International. Broad incumbents are Canopy Growth Corporation, Aurora Cannabis and Tilray Brands.

Does Vayamed have an API?

No public API is recorded for Vayamed.

What industry is Vayamed in?

Vayamed's product category is Specialty Pharmaceuticals / Medical Cannabis Distribution. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 42421 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business of Cannabis2026 Cannabis Consolidation: Mergers, Battles & PartnershipsHigh Tide's German subsidiary Remexian Pharma secured dual court victories against competitor Vayamed, with the Berlin Court of Appeal partially granting an injunction barring Vayamed from distributing disparaging statements about Remexian's Medicines Act compliance while Hamburg Regional Court issued a separate preliminary injunction against Malta-registered Dr Ansay Ltd for violations of Germany's Medicines Advertising Act. Australian medicinal cannabis companies Little Green Pharma and Cannatrek agreed to merge in an all-stock transaction creating a combined group with A$112 million in revenue and approximately 80 staff, positioning the entity as one of the largest vertically integrated cannabis businesses globally. Berlin-based Medios AG entered the medical cannabis market by securing exclusive distribution rights for Bedrocan's products across Germany, Spain, Belgium, Italy, and Austria, initially covering production from Bedrocan's EU-GMP certified facility in Denmark with expansion planned from 2027.GlobeNewswireMediPharm Labs Completes a New Cannabis Oil Delivery to German Partner VayamedMediPharm Labs shipped GMP-formulated cannabis oil to German partner Vayamed from its Victoria, Australia facility. The delivery supports MediPharm's goal of leveraging its pharmaceutical GMP licenses for international medical sales. The company expects additional deliveries under the strategic partnership.